Company intelligence / Profile preview

Eugia Pharma Specialities Limited

Hyderabad, Telangana, Indiaaurobindo.com ↗
Ownership
Private
Employees
~4000
Development stage
Commercial
01

Overview

Eugia has received multiple FDA approvals for various products including Icatibant Injection for hereditary angioedema treatment. The company has 166 ANDAs (including nine tentative approvals) from its facilities as of August 2023.

Therapeutic areas
OncologyEndocrinologyImmunology
Modalities
Small moleculesInjectables
Industry
Biotech
02

Drug pipeline

1 asset

midazolam eugia

Unknown

Beyond the preview

Go deeper on Eugia Pharma Specialities Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eugia Pharma Specialities Limited.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call